Current challenges in drug-resistant malaria

Journal of Postgraduate Medicine

Volumn 52, Issue 4, 2006, Pages 241-242

  Gogtay, N J ^a   Kshirsagar, N A ^a   Vaidya, A B ^b  

^a KEM HOSPITAL   (India)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (3 ACETYL 4,5 DIHYDRO 2 FURYLAMINO) 1 METHYLBUTYLAMINO] 6 METHOXYQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ATOVAQUONE; AZITHROMYCIN; CHLOROQUINE; DB 289; DIAMINE DERIVATIVE; DIHYDROARTEMISININ; DIHYDROARTEMISININ DERIVATIVE; FANSIDAR; ISOQUINE; MEFLOQUINE; OZ 277; PIPERAQUINE; PIPERQUINE; PRIMAQUINE; QUININE; TAFENOQUINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; EDITORIAL; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIA; MALARIA; MALARIA CONTROL; MORBIDITY; MORTALITY; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POPULATION RESEARCH; RELAPSE;

ANTIMALARIALS; DRUG RESISTANCE; HUMANS; MALARIA;

EID: 33845268634     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. WHO. Malaria fact sheet no 94. World Health Organization: Geneva; 1996.
2. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004;48:4075-83.
3. Garg M, Gopinathan N, Bodhe PV, Kshirsagar NA. Vivax malaria resistant to chloroquine- case reports from Bombay. Trans R Soc Trop Med Hyg 1995;89:656-7.
4. Philips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis 1996;23:1171-3.
5. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004;39:1336-45.
6. Rajgor DD, Gogtay NJ, Kadam VS, Kamtekar KD, Dalvi SS, Chogle AR, et al. Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Trans R Soc Trop Med Hyg 2003;97:438-40.
7. Craig AA, Kain KC. Molecular analysis of Plasmodium vivax from paired primary and relapse infections. J Infect Dis 1996;174:373-9.
8. Kirchgatter K, del Portillo HA. Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis 1998;177:511-5.
9. Ranque S, Badiaga S, Delmont J, Brouqui P. Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections. Malar Jr 2002;1:13.
10. Gogtay NJ, Kamtekar KD, Dalvi SS, Chogle AR, Aigal U, Kshirsagar NA. Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Ann Trop Med Parasitol 2004;98:525-8.
11. Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 2004;39:1095-103.
12. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Inf Dis 2002;2:209-18.
13. Greenwood BM, Bojang K, Whitty CJM, Targett GA. Malaria. Lancet 2005;365:1487-98.
14. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004;364:285-94.
15. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunat-mefloquine in falciparum malaria: An open label randomized comparison. Lancet 2006;367:2075-85.
16. Duffy PE, Mutabingwa TK. Artemisinin combination therapies. Lancet 2006;367:2037-9.
17. Green MD. Antimalarial drug resistance and the importance of drug quality monitoring. J Postgrad Med 2006;52:288-90.
18. Rozendaal J. Fake anti malarials circulating in Cambodia. Mekong Malaria Forum 2000;7:62-9.
19. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, et al. Manslaughter by fake artesunate in Asia- will Africa be next? PloS Med 2006;3:e197.
20. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J, et al. Assessment of pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001;357:1933-6.
21. Newton PN, Green MN, Fernandez FM, Day NPJ, White NJ. Counterfeit anti-infective drugs. Lancet Inf Dis 2006;6:602-13.
22. Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 2006;440:940-3.
23. Biagini GA, O'Neill PM, Bray PG, Ward SA. Current drug development portfolio for antimalarial therapies. Curr Opin Pharmacol 2005;5:473-8.